Case 1:18-cr-00567-VSB Document 161-1 Filed 01/16/20 Page 1 of 6

&YIJCJU
"
010213434 5667869

161-1
Case 1:18-cr-00567-VSB Document 6 ÿÿ
9Filed
ÿ
8 01/16/20
ÿÿ5 Page 2 of 6
5667869

6 5667869

6 ÿÿ
9ÿ
8
+9
ÿ6


9 5667869

6 ÿÿ
9ÿ
8
+9

!76ÿ6%776 
9ÿ
8 ÿ!76ÿ667869

6 ÿ%7ÿ $7/6ÿ7ÿ75ÿ&
/ 

#555,6ÿ#77258,96&5+62,#!ÿ$#7#,60ÿ:##$;
5667869

6 &


ÿ


6ÿ3'1421340*ÿ6ÿ3'1421340*
,7- 58,#!6ÿÿ96/
ÿ7%ÿ976ÿ97

667869

6 7 3
ÿ ÿ ÿ678ÿ 
ÿ98
6ÿ97
ÿ%7ÿ ÿ976ÿ?@AÿCADÿEFGAÿHIÿ<J?K<ÿ

ÿ
7ÿ%7ÿÿ%8ÿ 7ÿ7%ÿ5
<==><
5ÿ !7
ÿ5ÿ31ÿ8
6ÿ)ÿ0*ÿW6ÿ34cd`edÿJ\
+
.78 ÿ6/ÿ 97
ÿ8
ÿÿ ÿ976

9ÿ%7ÿ  

ÿ
7ÿ%7
667869

6 +
.78 ÿ97
ÿ8
ÿÿ ÿ976
0.
6 5667869

6 ÿ


ÿ ÿ##$
5ÿ31ÿ
7 LMNA OPHEAÿIACIQ
,rII
RAMGSHCA I
I2
%8ÿ#6%776
L _ l_ _ 11

!7
ÿ6ÿ
97 3'1421340* ,6/ÿ9
!6/ 03T'ÿ+7 ÿ'ÿ/
ÿ''T'U4
!987
2976/ÿ%7 97ÿ6ÿ
6ÿ
ÿ976ÿ667869

6 ÿ8 
ÿ76ÿ 978
)6ÿÿ73
 Vÿ6
ÿ
ÿ 8
ÿ
ÿ.
ÿ%7ÿ0ÿW68ÿ0XXYÿ7ÿ'4ÿW86
ÿ344'
473
ÿ&
7 +
.78 ÿ97
ÿ8
ÿÿ ÿ976
##$ÿ96/
ÿ7ÿ5,
ZHADHC[ÿ\MP]ANÿJCCF^CEA_ACNI`
2
 ÿ7%ÿ57
ÿ597ÿ&

ÿ.
 76ÿ244ÿÿ.
ÿ%%98ÿ99
6/ÿ+0)ÿ667869

6 ÿ7 ÿ698

7ÿ767 aÿ63ÿ798
6 aÿ6ÿ ÿ
ÿ7
ÿ
6/ÿ6ÿ
ÿ+0)ÿb
ÿ
97
6ÿ78ÿ767ÿ


ÿ.
 76ÿ7%ÿ
ÿ%

ÿ57
ÿ597ÿ&

ÿ,7ÿ9
93ÿ9ÿ.
 76ÿ78ÿ.
aÿ7
6ÿ57
ÿ597ÿ&

aÿ993
76ÿ-9
-aÿ
6ÿ993ÿ-578ÿ57
ÿ&

ÿ24-

 11 9781 1  9 1667869


6 7  !7
" !7
##$"
%
&"
&


 3'(3)42(3)340* 010
Case 1:18-cr-00567-VSB Document 161-1 Filed 01/16/20 Page 3 of 6

%JWJEFS
1BHF

*OUFOUJPOBMMZ
-FGU
#MBOL
 Case 1:18-cr-00567-VSB Document 161-1 Filed 01/16/20 Page 4 of 6

•ASX
MARKET RELEASE
23 June 2017

Innate lmmunotherapeutics Limited

TRADING HALT

The securities of Innate lmmunotherapeutics Limited (the "Company") will be placed in Trading Halt Session
State at the request of the Company, pending the release of an announcement by the Company. Unless ASX
decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the
commencement of norma l t rading on Tuesday, 27 June 2017 or when the announcement is released to the
market.

Security Code: Ill

(( )
)1

(( .J) George Tharian

l
I ADVISER, LISTINGS COMPLIANCE (SYDNEY)
 Case 1:18-cr-00567-VSB Document 161-1 Filed 01/16/20 Page 5 of 6

Innate
lmmunatherapeutics
ABN 16 165 160 841

23 June 2017

Mr. George Tharian

Adviser, Listings Compliance (Sydney)
Australian Securities Exchange

George.Tharian@asx.com.au
&
tradinghaltssydney@asx.com.au

REQUEST FOR TRADING HALT

Innate lmmunotherapeutics Limited (ASX Code : Ill) requests a Trading Halt in the securities of Ill
effective immediately this Friday 23 June 2017.

For the purposes of Listing Rule 17.1, Ill provides the following information:

a) The Trading Halt is necessary as the Company has received results from its Phase 2B trial of
M IS416 in patients with secondary progressive multiple sclerosis (SPMS).

b) The Company requests its securities remain in a trading halt for two days to resume trading on
Tuesday 27 June 2017.

c) The event which the Company expects will end the trading halt will be the lodgement of an
announcement regarding the results of the trial.

d) The Company is not aware of any reason why the trading halt should not be granted.
./

Yours sincerely,

.;;/A~~fj-
Company Secretary
( )

Suite 401, 35 Lime Street, Sydney 2000, Australia

AU Phone: +61 2 8003 3650 NZ Phone: +64 9 525 0532
Email info@innateimmuno.com
www.innateimmuno.com
 Case 1:18-cr-00567-VSB Document 161-1 Filed 01/16/20 Page 6 of 6

About Innate lmmunotherapeutfcs

Innate lmmunotherapeutics Limit ed is an Australian biotechnology company with an exciting technology that targets the
human innate immune system. The innate immune system is the body's first line of defence against external disease
ca using pathogens such as bacteria and viruses, and internally caused diseases such as cancer. Disorders of the immune
system can also cause or contribute to diseases such as multiple sclerosis. While the innate immune system is responsible
for mounting the body's initial defence against th reats, it also plays a critical role in controlling the overall immune
response and many for the body's tissue protective and reparatlve functions.

SPMS - The Significant Unmet Medical Need

((
Multiple sclerosis is a chronic disabling condition where the body's immune system attacks the myelin sheath surrounding
nerve fibres. The damaged myelin forms scar tissue which distorts or interrupts nerve impulses, disrupting the ability of
parts of the nervous syst em to communicate properly. This can result in a wide range of symptoms, including loss of
balance, muscle coordination, difficulty walking, slurred speech, tremors, stiffness, cognitive impairment, depression,
fatigue and bladder problems.

Within 15 years of being diagnosed with the early 'relapsing-remitting' stage of MS, and despite the 12 drugs approved to
,,. I treat this early stage of disease, about 60% of sufferers go on to develop a more advanced progressive form of disease -

VI!.)' SPMS. After 20 years the number of SPMS sufferers increases to about 75%. There are currently no approved drugs for
the effective ongoing treatment of SPMS. The Company's clinical development of M IS416 seeks to address this important
unmet medical need and significant commercial opportunity.
0-ljj About MIS416
The microparticle, MIS416, is a biologically derived novel immune modulator which can uniquely target both the regulatory
.,., and defensive functions of the innate immune system. MIS416 targets myeloid cells, a sub-set of innate immune cells not
,,' currently targeted by any other drugs in development for the treatment of SPMS.

Myeloid cells can play an important role inside the brain of a patient wit h SPMS by down regulating inflammation, helping
clear myelin debris, and upregulating t issue repair processes.
I,
I

(r
, .,
~/

,.II
J

1· •
I
·'i